Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$2.44 USD
+0.27 (12.44%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.45 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.44 USD
+0.27 (12.44%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.45 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Zacks News
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -15.63% and 1.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LHC Group (LHCG) Ties Up to Improve Home Health Services
by Zacks Equity Research
LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.
Illumina (ILMN) Invests in Seven Additional Genomics Startups
by Zacks Equity Research
Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.
Why Is Pacific Biosciences (PACB) Down 13.6% Since Last Earnings Report?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PacBio (PACB) Supports SickKids With Sequencing Technology
by Zacks Equity Research
PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN
by Debanjana Dey
The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.
DaVita's (DVA) Collaboration to Aid in Kidney Care Needs
by Zacks Equity Research
DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.
PacBio (PACB) to Leverage Google's Deep Learning Technologies
by Zacks Equity Research
PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
by Zacks Equity Research
PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.
Company News for Jan 12, 2022
by Zacks Equity Research
Companies in The News Are: ACCD,PACB,BIG,ILMN
PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability
by Zacks Equity Research
PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.
PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada
by Zacks Equity Research
PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.
PacBio's (PACB) New Surveillance Kit Successful Against Omicron
by Zacks Equity Research
PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research
by Zacks Equity Research
PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.
PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis
by Zacks Equity Research
PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.
PacBio's (PACB) New Solution to Boost Public Health Protection
by Zacks Equity Research
PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.
PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.